In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia

Leukemia

Volumn 27, Issue 12, 2013, Pages 2404-2407

  Strullu, M ^a,b   Caye, A ^a,b   Cassinat, B ^b,c   Fenneteau, O ^a   Touzot, F ^d   Blauwblomme, T ^d   Rodriguez, R ^e   Latour, S ^e   Petit, A ^f   Barlogis, V ^g   Galambrun, C ^g   Leblanc, T ^a   Baruchel, A ^a   Chomienne, C ^b,c   Cave H ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSERM   (France)

^f ARMAND TROUSSEAU HOSPITAL   (France)

^g TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; CORTICOSTEROID; MERCAPTOPURINE; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; CHILDHOOD CANCER; GENE MUTATION; HEMATOPOIETIC CELL; HETEROZYGOSITY LOSS; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LETTER; NF1 GENE; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BONE MARROW CELLS; CHILD, PRESCHOOL; FEMALE; GERM-LINE MUTATION; HUMANS; INFANT; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; LOSS OF HETEROZYGOSITY; MALE; PEDIGREE; PROTO-ONCOGENE PROTEINS C-CBL;

EID: 84890439281     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.203     Document Type: Letter

References (14)

1. Kales S, Ryan PE, Nau MM, Lipkowitz S. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res 2010; 70: 4789-4794.
2. Martinelli S, ADe Luca, Stellacci E, Rossi C, Checquolo S, Lepri F et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 2010; 87: 250-257.
3. Pé rez B, Mechinaud F, Galambrun C, Romdhane NBen, Isidor B, Philip N et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet 2010; 47: 686-691.
4. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010; 42: 794-800.
5. Pé rez B, Kosmider O, Cassinat B, Renneville A, Lachenaud J, Kaltenbach S et al. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br J Haematol 2010; 151: 460-468.
6. Muramatsu H, Makishima H, Jankowska AM, Cazzolli H, O'Keefe C, Yoshida N et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood 2010; 115: 1969-1975.
7. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res 2009; 33: 355-362.
8. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol 2011; 152: 677-687.
9. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009; 114: 1859-1863.
10. Cambier N, Menot ML, Schlageter MH, Balitrand N, Leblanc T, Bordigoni P et al. All trans retinoic acid abrogates spontaneous monocytic growth in juvenile chronic myelomonocytic leukaemia. Hematol J 2001; 2: 97-102.
11. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904-908.
12. Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res Off J Am Assoc Cancer Res 2009; 15: 2238-2247.
13. Kohlmann A, Klein HU, Weissmann S, Bresolin S, Chaplin T, Cuppens H et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011; 25: 1840-1848.
14. Takagi M, Piao J, Lin L, Kawaguchi H, Imai C, Ogawa A et al. Autoimmunity and persistent RAS-mutated clones long after the spontaneous regression of JMML. Leukemia 2013; 27: 1926-1928.